Pramlintide or mealtime insulin added to basal insulin treatment in patients with type 2 diabetes

被引：0
|
作者：
Riddle, M. [1 ]
Pencek, R. [2 ]
Charenkavanich, S. [2 ]
Lutz, K. [2 ]
Porter, L. [2 ]
Wilhelm, K. [2 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1007
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [1] Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
    Riddle, Matthew
    Pencek, Richard
    Charenkavanich, Supoat
    Lutz, Karen
    Wilhelm, Ken
    Porter, Lisa
    [J]. DIABETES CARE, 2009, 32 (09) : 1577 - 1582
  • [2] Comparison of Mealtime Pramlintide, Insulin, or a Combination of Both, When Added to Basal Insulin Treatment in Patients with Type 2 Diabetes
    Karounos, Dennis
    Pencek, Rich
    Huang, Wenying
    Miller, Stephan
    Lutz, Karen
    Porter, Lisa
    [J]. DIABETES, 2009, 58 : A32 - A32
  • [3] Comparison of mealtime pramlintide, insulin, or a combination of both, when added to basal insulin treatment in patients with type 2 diabetes
    Karounos, D.
    Pencek, R.
    Huang, W.
    Miller, S.
    Lutz, K.
    Porter, L.
    [J]. DIABETOLOGIA, 2009, 52 : S358 - S358
  • [4] Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study
    Pencek, R.
    Roddy, T.
    Peters, Y.
    De Young, M. B.
    Herrmann, K.
    Meller, L.
    Nguyen, H.
    Chen, S.
    Lutz, K.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (06): : 548 - 551
  • [5] Pramlintide improved glycemic control and reduced body weight in patients with type 2 diabetes treated with basal insulin (without mealtime insulin) and a thiazolidinedione
    Lorenzi, Gayle
    Frias, Juan
    Lutz, Karen
    Kesty, Nicole
    Zhang, Bei
    Kolterman, Orville
    [J]. DIABETES, 2007, 56 : A147 - A147
  • [6] Effect of pramlintide treatment on markers of cardiovascular risk in patients with type 2 diabetes using basal insulin
    Lush, C.
    Zhang, B.
    Maggs, D.
    Darsow, T.
    Kolterman, O.
    [J]. DIABETOLOGIA, 2007, 50 : S514 - S514
  • [7] Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs
    Peyrot, Mark
    Rubin, Richard R.
    Polonsky, William H.
    Best, Jennie H.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1047 - 1054
  • [8] Mealtime amylin replacement with pramlintide markedly reduced postprandial glucose excursions when added to insulin lispro in patients with type 1 or type 2 diabetes
    Weyer, C
    Kim, D
    Burrell, T
    Wang, Y
    Kornstein, J
    Bicsak, T
    Fineman, M
    Ruggles, J
    Schwartz, S
    Kolterman, O
    [J]. DIABETES, 2003, 52 : A16 - A16
  • [9] A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN
    Kalsekar, A.
    Bonafede, M. M.
    Pawaskar, M. D.
    McGuffie, K.
    Torres, A.
    Kelly, K. R.
    Curkendall, S.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A413 - A413
  • [10] Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes
    Wysham, Carol
    Lush, Cameron
    Zhang, Bei
    Maier, Holly
    Wilhelim, Ken
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 79 - 85
12345